231 related articles for article (PubMed ID: 7905013)
1. A new dosing regimen for esmolol to treat supraventricular tachyarrhythmia in Chinese patients.
Ko WJ; Chu SH
J Am Coll Cardiol; 1994 Feb; 23(2):302-6. PubMed ID: 7905013
[TBL] [Abstract][Full Text] [Related]
2. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias.
Gray RJ; Bateman TM; Czer LS; Conklin CM; Matloff JM
J Am Coll Cardiol; 1985 Jun; 5(6):1451-6. PubMed ID: 2860148
[TBL] [Abstract][Full Text] [Related]
3. Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias.
Balser JR; Martinez EA; Winters BD; Perdue PW; Clarke AW; Huang W; Tomaselli GF; Dorman T; Campbell K; Lipsett P; Breslow MJ; Rosenfeld BA
Anesthesiology; 1998 Nov; 89(5):1052-9. PubMed ID: 9821992
[TBL] [Abstract][Full Text] [Related]
4. Intravenous esmolol for the treatment of supraventricular tachyarrhythmia: results of a multicenter, baseline-controlled safety and efficacy study in 160 patients. The Esmolol Research Group.
Am Heart J; 1986 Sep; 112(3):498-505. PubMed ID: 2875641
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of esmolol (ASL-8052: an ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias.
Byrd RC; Sung RJ; Marks J; Parmley WW
J Am Coll Cardiol; 1984 Feb; 3(2 Pt 1):394-9. PubMed ID: 6141193
[TBL] [Abstract][Full Text] [Related]
6. Interactions of esmolol and adenosine in atrioventricular nodal-dependent supraventricular tachycardia: implication for the cellular mechanisms of adenosine.
Chang KC; Lin YC; Chen JY; Chou HT; Hung JS
Cardiology; 2002; 97(3):138-46. PubMed ID: 12077566
[TBL] [Abstract][Full Text] [Related]
7. Esmolol in the treatment of supraventricular tachyarrhythmias.
Das G; Ferris J
Can J Cardiol; 1988 May; 4(4):177-80. PubMed ID: 2899451
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and tolerance of esmolol to propranolol for control of supraventricular tachyarrhythmia.
Morganroth J; Horowitz LN; Anderson J; Turlapaty P
Am J Cardiol; 1985 Oct; 56(11):33F-39F. PubMed ID: 2864847
[TBL] [Abstract][Full Text] [Related]
9. Esmolol: safety and efficacy in postoperative cardiothoracic patients with supraventricular tachyarrhythmias.
Schwartz M; Michelson EL; Sawin HS; MacVaugh H
Chest; 1988 Apr; 93(4):705-11. PubMed ID: 2894920
[TBL] [Abstract][Full Text] [Related]
10. Comparison of esmolol and nitroprusside for acute post-cardiac surgical hypertension.
Gray RJ; Bateman TM; Czer LS; Conklin C; Matloff JM
Am J Cardiol; 1987 Apr; 59(8):887-91. PubMed ID: 2881481
[TBL] [Abstract][Full Text] [Related]
11. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
Barbier GH; Shettigar UR; Appunn DO
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
[TBL] [Abstract][Full Text] [Related]
12. Control of tachycardia and hypertension following coronary artery bypass graft surgery: efficacy and haemodynamic effects of esmolol.
Tempe DK; Mulchandani P; Tandon MS; Mehta N; Tomar AS; Banerjee A; Khanna SK
Indian Heart J; 1999; 51(3):294-300. PubMed ID: 10624069
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and antiarrhythmic effects of esmolol in children.
Trippel DL; Wiest DB; Gillette PC
J Pediatr; 1991 Jul; 119(1 Pt 1):142-7. PubMed ID: 1676729
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics and therapeutic efficacy of esmolol.
Wiest DB; Haney JS
Clin Pharmacokinet; 2012 Jun; 51(6):347-56. PubMed ID: 22515557
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia.
Sung RJ; Blanski L; Kirshenbaum J; MacCosbe P; Turlapaty P; Laddu AR
J Clin Pharmacol; 1986 Mar; 26(S1):A15-A26. PubMed ID: 2870082
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of esmolol in the treatment and transfer of patients with supraventricular tachyarrhythmias to alternate oral antiarrhythmic agents.
Das G; Tschida V; Gray R; Dhurandhar R; Lester R; McGrew F; Askenazi J; Kaplan K; Emanuele M; Turlapaty P
J Clin Pharmacol; 1988 Aug; 28(8):746-50. PubMed ID: 2905710
[TBL] [Abstract][Full Text] [Related]
17. Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study.
Xiao J; He P; Zou Q; Zhao Y; Xue Z; Deng X; Li S; Guo Q; Tao G; Yang T; Lang Z; He J; Wang X
J Clin Anesth; 2015 Mar; 27(2):120-8. PubMed ID: 25434501
[TBL] [Abstract][Full Text] [Related]
18. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.
Angaran DM; Schultz NJ; Tschida VH
Clin Pharm; 1986 Apr; 5(4):288-303. PubMed ID: 2871961
[TBL] [Abstract][Full Text] [Related]
19. Esmolol for treatment of intraoperative tachycardia and/or hypertension in patients having cardiac operations. Bolus loading technique.
Reves JG; Croughwell ND; Hawkins E; Smith LR; Jacobs JR; Rankin S; Lowe J; VanTrigt P
J Thorac Cardiovasc Surg; 1990 Aug; 100(2):221-7. PubMed ID: 1974664
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group.
Anderson S; Blanski L; Byrd RC; Das G; Engler R; Laddu A; Lee R; Rajfer S; Schroeder J; Steck JD
Am Heart J; 1986 Jan; 111(1):42-8. PubMed ID: 2868645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
